Amphetamine Stimulant denied due to quantity / dose limits by UnitedHealthcare?

UnitedHealthcare's specific coverage criteria for amphetamine stimulant are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why UnitedHealthcare Limits Amphetamine Stimulant Quantities — and How to Appeal

Quantity limits for amphetamine stimulants are applied by UnitedHealthcare to restrict the number of tablets, capsules, or total supply dispensed within a given coverage period. These limits are designed to align with standard dosing patterns, but they create problems for patients whose prescribed regimen — determined by their treating physician based on individual response and clinical need — exceeds the plan's threshold. Common trigger scenarios include higher-than-typical prescribed doses, overlapping fills during a regimen transition, or a supply request that does not fit neatly into the plan's standard dosing assumptions.

Quantity-limit denials are appealable. The plan's limit is a default, not a clinical determination about your specific needs.

## Your Federal Appeal Rights

• Internal appeal (ERISA §503): You are entitled to a full-and-fair review that considers your individual clinical circumstances. The plan must explain the specific quantity-limit rule applied and allow you to submit clinical evidence that your prescribed amount is medically necessary.
• External review (ACA §2719): If the internal appeal is denied, file for independent external review within the window stated in your denial letter — typically approximately 180 days from the final internal denial. The IRO applies recognized clinical standards, not UHC's internal limits alone.
• Expedited review: If the quantity limitation is preventing adequate treatment of a condition that poses an urgent risk, request expedited processing. Plans typically must respond within 72 hours.

## Documentation to Gather

1. Prescriber quantity-justification letter — A signed letter from the treating physician explaining why the prescribed quantity is medically necessary for this patient, how it was determined, and why the plan's default limit is clinically insufficient. 2. Diagnosis and severity documentation — Chart notes confirming the diagnosis, symptom burden, and any factors (body weight, metabolism, treatment-refractory history) that inform the dosing rationale. Do not include specific dose figures in your appeal summary — let the prescriber's letter and FDA label speak to those. 3. Prior medication response history — Documentation of how the patient responded to lower quantities or different regimens, supporting the clinical logic of the current prescription. 4. FDA prescribing label alignment — The prescriber should confirm that the prescribed quantity is consistent with the dosing range described in the FDA-approved prescribing information for the patient's condition. 5. Functional-impact evidence — Records showing how under-treatment (due to quantity restriction) affects daily functioning, safety, or occupational performance.

## Criteria-Mapping Strategy

Request UHC's quantity-limit policy for amphetamine stimulants and identify the specific threshold your prescription exceeded. For each criterion the policy sets, provide a direct chart-based answer. The most persuasive appeals combine a prescriber's individualized clinical narrative with a structured criterion-by-criterion mapping — leaving no requirement unaddressed.